




RN: 619811-96-3 CAPLUS
CN: Piperazine, 1-(2-cyanophenoxy)-4-((2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)phenyl)acetyl)- (PCP) (CA INDEX NAME)




RN: 619811-04-2 CAPLUS
CN: 2-Piperidinol, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)phenyl)acetyl]- (PCP) (CA INDEX NAME)




RN: 619811-01-7 CAPLUS
CN: 2-Piperidinemethanol, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)phenyl)acetyl]- (PCP) (CA INDEX NAME)




RN: 619811-02-4 CAPLUS
CN: 2-Piperidinocarboxamide, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)phenyl)acetyl]- (PCP) (CA INDEX NAME)




RN: 619811-02-5 CAPLUS
CN: 2-Piperidinocarboxamide, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)phenyl)acetyl]- (PCP) (CA INDEX NAME)



RN: 619811-04-6 CAPLUS
CN: 2-Piperidinol, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)phenyl)acetyl]- (PCP) (CA INDEX NAME)




RN: 619811-05-7 CAPLUS
CN: Butanenecetamide, N-(2-3-dihydroxypropyl)-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)-N-methyl- (PCP) (CA INDEX NAME)




RN: 619811-07-9 CAPLUS
CN: Butanenecetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)-N-(3-


10/561415
pyridinylmethyl)- (PCP) (CA INDEX NAME)




RN: 619811-09-1 CAPLUS
CN: Piperazine, 2-((2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)phenyl)acetyl)-4-phenyl- (PCP) (CA INDEX NAME)



RN: 619811-10-1 CAPLUS
CN: 4-Piperidinol, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)phenyl)acetyl]-4-phenyl- (PCP) (CA INDEX NAME)




RN: 619811-11-5 CAPLUS
CN: Piperazine, 2-((2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)phenyl)acetyl)-4-(4-pyridinyl)- (PCP) (CA INDEX NAME)




10/561415
STIC


RN: 619811-12-6 CAPLUS
CN: Butanenecetamide, 2-ethyl-3,5-dihydroxy-N-[1-hydroxyethyl]-6-(4-methoxybenzyl)-N-(1-methoxyethyl)- (PCP) (CA INDEX NAME)




RN: 619811-14-8 CAPLUS
CN: Piperazine, 2-((2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)phenyl)acetyl)-4-(2-methoxyphenyl)- (PCP) (CA INDEX NAME)



RN: 619811-15-9 CAPLUS
CN: Piperazine, 2-acetyl-4-(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)phenyl)acetyl)-4-(2-methoxyphenyl)- (PCP) (CA INDEX NAME)



RN: 619811-16-0 CAPLUS
CN: Piperazine, 2-((2-ethyl-3,5-dihydroxy-6-(4-methoxybenzyl)phenyl)acetyl)-4-methyl- (PCP) (CA INDEX NAME)




RN: 619811-17-1 CAPLUS


10/561415

STIC


RU 819811-16-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)acetyl-
1,2,3,4-tetrahydro-4,7-dimethoxy (9CI) (CA INDEX NAME)



RU 819811-16-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-N-(2-furylmethyl)-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)




RU 819811-19-3 CAPLUS
CN 1-Piperazinehexaenol, 4-[{2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl- (9CI) (CA INDEX NAME)




RU 819811-20-6 CAPLUS
CN Piperazine, 1-[{2-(4-dimethoxybenzoyl)-6-oxo-3,5-dihydroxyphenyl}acetyl]-1-phenyl- (9CI) (CA INDEX NAME)

10/561415


STIC




RU 819811-21-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RU 819811-22-8 CAPLUS
CN Piperazine, 1-[{2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl}acetyl]-4-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RU 819811-23-9 CAPLUS
CN Morpholine, 4-[{2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl}acetyl]- (9CI) (CA INDEX NAME)



RU 819811-24-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(3-{2-oxo-1-


9

10


10/561415

STIC


p-methylbenzyl)pyrrolidin-2-yl- (9CI) (CA INDEX NAME)




RU 819811-26-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(2-hydroxy-1-(hydroxymethyl)ethyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



RU 819811-27-3 CAPLUS
CN Benzeneacetamide, 2-ethyl-1,3,5-dihydroxy-6-(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




RU 819811-28-6 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxyphenyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




10/561415

STIC


RU 819811-29-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RU 819811-32-1 CAPLUS
CN Imidazolidine, 5-[(2-ethyl)-6-(4-fluorobenzoyl)-3,5-dihydroxybenzoyl]acetyl-1,2,5,4-tetrahydro-4,7-dimethoxy- (9CI) (CA INDEX NAME)



RU 819811-36-2 CAPLUS
CN Pyrazole, 1-[{2-ethyl-3,5-dihydroxy-6-(4-hydroxybenzoyl)phenyl}acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RU 819811-37-0 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




11

12


RN: 619811-40-2 CAPLUS
CN: 4-(Fluorodimethylsilyl)-1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-1-phenyl- (SC1) (CA INDEX NAME)




RN: 619811-43-1 CAPLUS
CN: 4-(Fluorodimethylsilyl)-1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-1-phenyl- (SC1) (CA INDEX NAME)




RN: 619811-46-9 CAPLUS
CN: Benzeneacetamide, 2-ethyl-4-(4-fluorobenzoyl)-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (SC1) (CA INDEX NAME)




RN: 619811-46-6 CAPLUS
CN: Piperidina, 3-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-4-(methylsulfonyl)- (SC1) (CA INDEX NAME)




RN: 619811-56-8 CAPLUS
CN: Benzeneacetamide, 2-Benzoyl-6-ethyl-3,5-dibhydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (SC1) (CA INDEX NAME)




RN: 619811-57-9 CAPLUS
CN: 4-Piperidinomethylsilyl-1-[(2-benzoyl-6-ethyl-3,5-dibhydroxyphenyl)acetyl]- (SC1) (CA INDEX NAME)




RN: 619811-58-C CAPLUS
CN: Benzeneacetamide, 2-ethyl-3,5-dibhydroxy-6-(2-hydroxyethyl)-N-(2-methoxyethyl)- (SC1) (CA INDEX NAME)




RN: 619811-59-1 CAPLUS
CN: Benzeneacetamide, 2-ethyl-1-[(2,5-dihydroxy-6-(4-hydroxybenzoyl)phenyl)-N-(2-hydroxyethyl)]- (SC1) (CA INDEX NAME)




RN: 619811-59-3 CAPLUS
CN: Benzeneacetamide, 2-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-1-phenyl- (SC1) (CA INDEX NAME)




RN: 619811-59-8 CAPLUS
CN: Benzeneacetamide, 2-ethyl-3-[(2-furylmethyl)-3,5-dihydroxy-N-(2-hydroxyphenyl)-6-(4-methoxybenzoyl)- (SC1) (CA INDEX NAME)




RN: 619811-54-C CAPLUS
CN: Piperazine, 4-[(2-ethyl-6-ethyl-3,5-dibhydroxyphenyl)acetyl]-1-(2-cyanoethyl)- (SC1) (CA INDEX NAME)




RN: 619811-55-7 CAPLUS
CN: Benzeneacetamide, 2-benzoyl-6-ethyl-3,5-dibhydroxy-N,N-bis(2-hydroxyethyl)- (SC1) (CA INDEX NAME)




RN: 619811-56-4 CAPLUS
CN: Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-hydroxybenzoyl)-N-(1-hydroxyethyl)- (SC1) (CA INDEX NAME)



RN: 619811-51-5 CAPLUS
CN: Piperazine, 2-[(2-ethyl-6-4-fluorobenzoyl)-3,5-dihydroxyphenyl]acetyl]-1-phenyl- (SC1) (CA INDEX NAME)




RN: 619811-52-6 CAPLUS
CN: Benzeneacetamide, 2-ethyl-3,5-dibhydroxy-N,N-bis(2-hydroxyethyl)-6-(1-hydroxy-4-methoxybenzoyl)- (SC1) (CA INDEX NAME)




RN: 619811-53-7 CAPLUS
CN: Benzeneacetamide, 2-ethyl-3,5-dibhydroxy-6-(4-hydroxybenzoyl)-C-(4-methoxybenzoyl)- (SC1) (CA INDEX NAME)




RM: Benzenesuccinamide, 2-ethyl-3,5-dihydroxy-3-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN: 819611-10-8 CAPIUS
CN: Benzenesuccinamide, 2-ethyl-3,5-dihydroxy-3-(2-hydroxyethyl)-N-(2-hydroxyethyl)-6-(n-methoxybutyl)- (9CI) (CA INDEX NAME)




RM: 819611-11-9 CAPIUS
CN: Benzenesuccinamide, 2-ethyl-3,5-dihydroxy-3-(2-hydroxyethyl)-N-(2-methoxybutyl)-6-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN: 715-13-92-0 CAPIUS
CN: Benzenesuccinamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(2-methoxy-2-(2-methoxyethyl)ethoxybenzoyl)- (9CI) (CA INDEX NAME)





RM: 819611-17-1 CAPIUS
CN: Benzenesuccinamide, 2-ethyl-3,5-dihydroxy-3-(2-hydroxyethyl)-N-(2-methoxyethyl)-N-(2-hydroxyethyl)-6-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RM: 612A11-08-6 CAPIUS
CN: Benzenesuccinamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(2-methoxy-4-(2-methoxyethyl)benzoyl)- (9CI) (CA INDEX NAME)




RN: 819611-87-7 CAPIUS
CN: Benzenesuccinamide, 2-ethyl-3,5-dihydroxy-3-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(3-methoxy-4-(4-morpholinyl)ethoxybenzoyl)- (9CI) (CA INDEX NAME)




RM: 819611-13-1 CAPIUS
CN: Benzenesuccinamide, 2-ethyl-3,5-dihydroxy-3-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-methoxy-2-(2-(4-morpholinyl)ethoxy)benzoyl)- (9CI) (CA INDEX NAME)



RN: 819611-34-2 CAPIUS
CN: Benzenesuccinamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-hydroxy-3-methoxybenzoyl)-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN: 612A11-35-3 CAPIUS
CN: Benzenesuccinamide, 2-ethyl-3,5-dihydroxy-3-(4-hydroxy-5-methoxybenzoyl)-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN: 612A11-36-4 CAPIUS
CN: Benzenesuccinamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-(4-methyleufonylbenzoyl)- (9CI) (CA INDEX NAME)


RM: 819611-57-3 CAPIUS
CN: Benzenesuccinamide, 2-ethyl-3,5-dihydroxy-3-(2-hydroxyethyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




RM: 819611-61-1 CAPIUS
CN: Benzenesuccinamide, 2-(3,4-dimethoxyphenacyl)-6-(2-(dimethylaminolaminoethyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RM: 819611-62-3 CAPIUS
CN: Benzenesuccinamide, N-(2-(dimethylaminoethyl)-6-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RM: 819611-87-7 CAPIUS
CN: Benzenesuccinamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-N-(2-(4-morpholinyl)ethyl)- (9CI) (CA INDEX NAME)




RN: 619811-95-5 CASLUG
CN: Benzenacetamide, 2-ethyl-3-hydroxy-5-[4-methoxybenzoyl]-N-(2-methoxyethyl)-N-(2-(1-morpholinyl)ethyl)- (9CI) (CA INDEX NAME)




RN: 619811-96-6 CASLUG
CN: Benzenacetamide, 2-ethyl-3-hydroxy-N-(2-hydroxypropyl)-6-[4-methoxybenzoyl]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN: 619811-97-7 CASLUG
CN: Benzenacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-4-[4-methoxybenzoyl]-N-(2-methoxypropyl)- (9CI) (CA INDEX NAME)




RN: 719811-98-8 CASLUG
CN: Benzenacetamide, 2-(1,1-dimethylethoxybenzoyl)-4-ethyl-3,5-dihydroxy-N-(2-




RN: 619811-99-9 CASLUG
CN: Benzenacetamide, 2-(4-dimethoxybenzoyl)-4-ethyl-3,5-dihydroxy-N-(2-hydroxypropyl)- (9CI) (CA INDEX NAME)



RN: 619811-00-5 CASLUG
CN: Benzenacetamide, 2-(4-ethoxybenzoyl)-4-ethyl-3,5-dihydroxy-N-(2-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN: 619811-01-6 CASLUG
CN: Benzenacetamide, 2-(4-ethoxybenzoyl)-4-ethyl-3,5-dihydroxy-N-(2-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN: 619811-02-7 CASLUG
CN: Benzenacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(4-(2-methylethoxy)benzoyl)- (9CI) (CA INDEX NAME)

25


26




RN: 619811-03-8 CASLUG
CN: Benzenacetamide, 2-ethyl-3-hydroxy-5-[2-hydroxyethyl]-N-(2-methoxyethyl)-6-[4-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)




RN: 619811-05-0 CASLUG
CN: Benzenacetamide, 2-ethyl-3-hydroxy-5-[1-(2-hydroxyethyl)-2-methoxybenzoyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN: 619811-06-1 CASLUG
CN: Benzenacetamide, 2-(1,1-dimethylethoxybenzoyl)-N-(2-(dimethylamino)propyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN: 619811-07-2 CASLUG
CN: Benzenacetamide, 2-(1-(dimethylamino)propyl)-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN: 619811-08-3 CASLUG
CN: Benzenacetamide, N-[2-(dimethylamino)ethyl]-2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN: 619811-09-4 CASLUG
CN: Benzenacetamide, N-[2-(dimethylamino)ethyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN: 619811-10-7 CASLUG
CN: Piperidine, 1-[1-(1,4-dimethoxybenzoyl)-4-oxo-3,4-dihydrophenyl]-4-(4-methoxyethyl)- (9CI) (CA INDEX NAME)




RN: 619811-11-8 CASLUG
CN: Piperidine, 1-[1-(4-methoxybenzoyl)-4-oxo-3,4-dihydrophenyl]-4-(4-methoxyethyl)- (9CI) (CA INDEX NAME)




BN: B19612-11-3 CAPILOB
CN: Benzeneacetamide, 1-[4-ethoxybenzoyl]-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (HCl) (CA INDEX NAME)




BN: B19612-13-2 CAPILOB
CN: Benzeneacetamide, 1-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-d-[(1-methoxymethyl)benzoyl]-N-[2-(4-morpholinyl)ethyl]- (HCl) (CA INDEX NAME)




BN: B19612-14-1 CAPILOB
CN: Benzeneacetamide, 2-hydroxy-3,5-dihydroxy-*D*-[2-hydroxyethyl]-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (HCl) (CA INDEX NAME)




BN: B19612-15-2 CAPILOB
CN: Benzeneacetamide, N-acetyl-3,5-dihydroxy-*D*-[2-hydroxyethyl]-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (HCl) (CA INDEX NAME)




BN: B19612-16-3 CAPILOB
CN: Benzeneacetamide, 1-[4-(2-methoxyethyl)benzoyl]-6-hydroxy-*D*-[2-methoxyethyl]benzeneacetamide, 2-[3,4-di-(2-methoxyethyl)benzoyl]-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-[2-(4-morpholinyl)ethyl]- (HCl) (CA INDEX NAME)




BN: B19612-17-4 CAPILOB
CN: Benzeneacetamide, 2-[3,4-di-(2-methoxyethyl)benzoyl]-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-[2-(4-morpholinyl)ethyl]- (HCl) (CA INDEX NAME)




BN: B19612-18-5 CAPILOB
CN: Benzeneacetamide, 2-ethyl-3,5-dihydroxy-*D*-[2-methoxyethyl]-6-[3-methoxy-*D*-[2-(4-morpholinyl)ethyl]benzoyl]-, monohydrochloride (HCl) (CA INDEX NAME)




● HCl



BN: B19612-19-4 CAPILOB
CN: Benzeneacetamide, 2-[3,4-dimethoxybenzoyl]-6-[2-(dimethylaminocarbonylmethyl)-2-oxoethyl]- (HCl) (CA INDEX NAME)





BN: B19612-19-5 CAPILOB
CN: Benzeneacetamide, N-(2-(dimethylaminocarbonylmethyl)-2-oxoethyl)-6-ethyl-3,5-dihydroxy-*D*-[2-methoxybenzoyl]-, monohydrochloride (HCl) (CA INDEX NAME)




● HCl


BN: B19612-19-7 CAPILOB
CN: Benzeneacetamide, 2-ethyl-3,5-dihydroxy-*D*-[2-methoxyethyl]-6-[2-(trifluoromethyl)benzoyl]- (HCl) (CA INDEX NAME)




BN: B19612-20-2 CAPILOB
CN: Benzeneacetamide, 1-ethyl-3,5-dihydroxy-*D*-[2-methoxyethyl]-6-[2-(trifluoromethyl)benzoyl]- (HCl) (CA INDEX NAME)



BN: B19612-20-3 CAPILOB
CN: Benzeneacetamide, 2-[3,4-difluorobenzoyl]-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (HCl) (CA INDEX NAME)




BN: B19612-20-4 CAPILOB
CN: Benzeneacetamide, 2-ethyl-3,5-dihydroxy-*D*-[2-methoxyethyl]-6-[2-(trifluoromethyl)benzoyl]- (HCl) (CA INDEX NAME)



10/561415


STIC

RU: Benzeneacetamide, 2-[1-(dimethylaminocarbonyl)-2-(3,4-dimethoxybenzoyl)-6-methyl-3-oxo-2-propenyl]-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RU: 819613-57-0 CAPLUS

Benzeneacetamide, 2-[1-(4-dimethoxybenzoyl)-4-ethyl-6-(2-methoxyethyl)-3,5-bis(2-propenyl)oxy]- (9CI) (CA INDEX NAME)



RU: 819613-51-9 CAPLUS

Benzeneacetamide, 2-ethyl-4-(4-methoxybenzoyl)-6-(2-methoxyethyl)-3,5-bis(2-propenyl)oxy)- (9CI) (CA INDEX NAME)




RU: 819613-56-4 CAPLUS

Benzeneacetamide, 2-ethyl-4-(4-hydroxy-2-methoxybenzoyl)-N,N-bis(2-methoxyethyl)-3,5-bis(2-propenyl)oxy)- (9CI) (CA INDEX NAME)




10/561415

STIC




RU: 819613-51-1 CAPLUS

Benzeneacetamide, 2-[1-(dimethylaminocarbonyl)ethyl]-2-(3,4-dimethoxybenzoyl)-6-methyl-N-(2-methoxyethyl)-3,5-bis(2-propenyl)oxy)- (9CI) (CA INDEX NAME)




RU: 819613-61-1 CAPLUS

Benzeneacetamide, N-[2-(dimethylaminocarbonyl)ethyl]-2-(3,4-dimethoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propenyl)oxy)- (9CI) (CA INDEX NAME)



RU: 819613-62-0 CAPLUS

Piperazine, 1-[1-(3,4-dimethoxybenzoyl)-3-oxo-1,3-dihydro-2-propenyl]-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RU: 819613-64-6 CAPLUS


Oxazepidine, 1-[1-(3,4-dimethoxybenzoyl)-2-oxo-1,3-dihydro-2-propenyl]-(2-methoxyethyl)- (9CI) (CA INDEX NAME)

10/561415


STIC




RU: 819613-57-7 CAPLUS
Benzeneacetamide, 2-[1-(2-methoxyethyl)-3-oxo-1,3-dihydro-2-propenyl]-N-(2-methoxyethyl)-3,5-bis(2-propenyl)oxy)- (9CI) (CA INDEX NAME)



RU: 819613-54-4 CAPLUS
Benzeneacetamide, 2-[1-(2-hydroxyethyl)-3-oxo-1,3-dihydro-2-propenyl]-N-(2-methoxyethyl)-3,5-bis(2-propenyl)oxy)- (9CI) (CA INDEX NAME)




RU: 819613-55-2 CAPLUS
Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-3-[2-(dimethylaminocarbonyl)-4-ethyl-6-(2-methoxyethyl)-3,5-bis(2-propenyl)oxy]- (9CI) (CA INDEX NAME)




RU: 819613-50-0 CAPLUS
Benzeneacetamide, N-[5-(dimethylaminocarbonyl)propyl]-2-ethyl-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propenyl)oxy)- (9CI) (CA INDEX NAME)


10/561415 STIC




RU: 819613-57-7 CAPLUS
Benzeneacetamide, 2-[1-(2-hydroxyethyl)-3-oxo-1,3-dihydro-2-propenyl]-N-(2-methoxyethyl)-3,5-bis(2-propenyl)oxy)- (9CI) (CA INDEX NAME)




RU: 819613-52-9 CAPLUS
Benzeneacetamide, 2-[1-(2-hydroxyethyl)-3-iodo-1,3-dihydro-2-propenyl]-N-(2-methoxyethyl)-3,5-bis(2-propenyl)oxy)- (9CI) (CA INDEX NAME)




RU: 819613-57-1 CAPLUS
Benzeneacetamide, 2-[1-(2-hydroxyethyl)-3-oxo-1,3-dihydro-2-propenyl]-N-(2-methoxyethyl)-3,5-bis(2-propenyl)oxy)- (9CI) (CA INDEX NAME)




RU: 819613-56-3 CAPLUS
Benzeneacetamide, 2-[1-(2-methoxyethyl)-3-oxo-1,3-dihydro-2-propenyl]-N-(2-methoxyethyl)-3,5-bis(2-propenyl)oxy)- (9CI) (CA INDEX NAME)




RN: 519612-52-1 CAPLUS
Benzeneacetoamide, 2-[1-(2-methoxyethyl)-2-methoxybenzyl]-4-ethoxy-6-
methyl(2-methoxyethyl)-3,5-bis(1-propenyloxy)- (ECI) (UK INDRX NAME)



RN: 519612-54-6 CAPLUS
Benzeneacetoamide, 2-ethyl 2-methyl 3,5-bis(2-methoxyethyl)-4-(3-methoxy-3-(2-(4-morpholinyl)-1-piperidinyl)ethoxy)benzyl-3,5-bis(1-propenyloxy)- (ECI) (UK INDRX NAME)




RN: 519612-55-5 CAPLUS
Benzeneacetoamide, 2-[4-(1-chloropropoxy)-2-methoxybenzoyl]-4-ethyl-N,N-dimethyl(2-methoxyethyl)-3,5-bis(1-propenyloxy)- (ECI) (UK INDRX NAME)




RN: 519612-56-4 CAPLUS


CAS REGISTRY NUMBER: 519612-52-1
SOURCE: CAPLUS
NAME:



RN: 519612-53-0 CAPLUS
Acrylic acid, 1-[2-(2-methoxyethyl)-2-methoxy-4-ethyl-6-methyl-3,5-bis(1-propenyloxy)benzyl] 2-methoxyphenoxy-, methyl ester (ECI) (UK INDRX NAME)



RN: 519612-54-6 CAPLUS
Benzeneacetoamide, 2-ethyl-N,N-bis[2-methoxyethyl]-4-[2-(4-methyl-1-piperidinyl)-2-oxoethoxy]benzyl-3,5-bis(1-propenyloxy)- (ECI) (UK INDRX NAME)



REFERRED COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

BROAD STRUCTURE + TEXT

> fil reg; d stat que 111; fil capl; d que nos 148; d que nos 151; a 148,151 not 144
FILE 'REGISTRY' ENTERED AT 15:08:48 ON 15 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI date file provided by Infocem.

STRUCTURE FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3
DICTIONARY FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stndoc/properties.html>

L8 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L11 625 SEA FILE=REGISTRY SSS FUL L8

100.01 PROCESSED 5028 ITERATIONS
SEARCH TIME: 00:00.01

625 ANSWERS

FILE 'CAPLUS' ENTERED AT 15:08:48 ON 15 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of ACS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2007 VOL 146 ISS 26
FILE LAST UPDATED: 14 Jun 2007 (20070614/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L8 STR
L11 625 SEA FILE=REGISTRY SSS FUL L8
L45 29025 SEA FILE=CAPLUS ABB=ON HEAT SHOCK/OBI OR HSP90/OBI OR HSP/OBI

L47 283 SEA FILE=CAPLUS ABB=ON L11
L48 1 SEA FILE=CAPLUS ABB=ON L47 AND L45

L8 STR
L11 625 SEA FILE=REGISTRY SSS FUL L8
L47 283 SEA FILE=CAPLUS ABB=ON L11
L49 166137 SEA FILE=CAPLUS ABB=ON ANTITUMOR AGENTS/CT
L50 484200 SEA FILE=CAPLUS ABB=ON NEOPLAST?/OBI
L51 8 SEA FILE=CAPLUS ABB=ON L47 AND (L49 OR L50)

L52 7 (L48 OR L51) NOT L44

> d ibib ed abs hitstr 1-7

L52 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006-245182 CAPLUS Full-text
DOCUMENT NUMBER: 145-241713
TITLE: Antitumor agent containing benzoyl compounds
INVENTOR(S): Kanda, Yukata; Soga, Shiro; Nakashima, Takayuki; Nara, Shinji; Nagakawa, Hiroshi; Shiotsu, Yuki
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 61pp.
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 200608193 A1 20060824 WO 2006-JP302996 200608221
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, OM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MM, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, PR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO, BW, OH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM


PRIORITY APPLN. INFO.:

JP2005-14843 CAPLUS A720050221

OTHER SOURCE(S): MARPAT 145:241713


ED Entered STN: 24 Aug 2006

GI




AB Disclosed is a therapeutic agent for a tumor selected from a hematopoietic tumor and a solid tumor, comprising, as the active ingredient, a benzoyl compound represented by the general formula I or a prodrug or pharmacol. acceptable salt thereof; I wherein n is an integer of 1 to 5; R1 represents a substituted or unsubstituted lower alkoxy, a substituted or unsubstituted lower alkoxycarbonyl, CON(R)R2 or the like; R2 represents a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R3 and R5 independently represent a hydrogen atom, a substituted or unsubstituted lower alkyl or the like; R4 represents a hydrogen atom, a hydroxyl or a halogen; and R6 represents a hydrogen atom, a halogen, a substituted or unsubstituted lower alkyl or the like. For example, the antitumor activity of a compound I (R1 = CON(CH2CH2OH)2; n = 1; R2 = p-methoxyphenyl; R3, R4, R5 = H; R6 = Et) was in vitro tested.


IT 819810-81-6 819810-82-7 819810-85-0
 819810-89-4 819810-92-9 819810-93-0
 819810-94-1 819810-95-2 819810-96-3
 819810-97-4 819810-98-5 819810-99-6
 819811-00-2 819811-01-3 819811-02-4
 819811-03-5 819811-04-6 819811-05-7
 819811-06-0 819811-07-1 819811-08-0
 819811-09-1 819811-10-2 819811-11-5
 819811-12-6 819811-14-8 819811-15-9
 819811-16-0 819811-17-1 819811-18-2
 819811-19-3 819811-20-6 819811-21-7
 819811-22-8 819811-23-9 819811-24-0
 819811-26-2 819811-27-3 819811-28-4




RN 819810-85-0 CAPLUS
 CN Benzenoacetic acid, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 819810-89-4 CAPLUS
 CN Benzenoacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 819810-92-9 CAPLUS
 CN Benzenoacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 819810-93-0 CAPLUS
 CN Benzenoacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)


819811-29-5 819811-33-1 819811-34-2
 819811-35-3 819811-40-0 819811-43-3
 819811-45-5 819811-46-6 819811-47-7
 819811-48-0 819811-54-8 819811-55-7
 819811-56-8 819811-57-9 819811-58-0
 819811-59-1 819811-60-4 819811-61-5
 819811-62-6 819811-63-7 819811-64-8
 819811-65-9 819811-66-0 819811-67-1
 819811-68-2 819811-69-3 819811-70-6
 819811-71-7 819811-72-8 819811-73-9
 819811-74-0 819811-75-1 819811-76-2
 819811-77-3 819811-78-4 819811-79-5
 819811-80-8 819811-81-9 819811-82-0
 819811-83-1 819811-84-2 819811-85-3
 819811-86-4 819811-87-5 819811-88-6
 819811-89-7 819811-90-8 819811-91-1
 819811-92-2 819811-93-3 819811-94-4
 819811-95-5 819811-96-6 819811-97-7
 819811-98-0 819811-99-1 819812-00-5
 819812-01-6 819812-02-7 819812-03-8
 819812-04-9 819812-05-0 819812-06-1
 819812-07-2 819812-08-3 819812-09-4
 819812-10-7 819812-11-8 819812-12-9
 819812-13-0 819812-14-1 819812-15-2
 819812-16-3 819812-17-4 819812-18-5
 819812-19-6 819812-20-7 819812-21-0
 819812-22-1 819812-23-2 819812-24-3
 819812-25-4 819812-26-5 819812-27-6
 819812-28-7 819812-29-8 819812-36-7
 819812-37-8

RL: PAC (Pharmacological activity); TNU (Therapeutic use); BIOL (Biological activity); USES (Uses)
 (antitumor agents containing benzoyl compds.)


RN 819812-01-6 CAPLUS
 CN Benzenoacetic acid, 2-benzoyl-6-ethyl-3,5-dihydroxy-, methyl ester (9CI)
 (CA INDEX NAME)




RN 819810-82-7 CAPLUS
 CN Benzenoacetic acid, 2-ethyl-3,5-dihydroxy-6-(3-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 819810-94-1 CAPLUS
 CN Benzenoacetic acid, 3,5-dihydroxy-2-iodo-6-(4-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 819810-95-2 CAPLUS
 CN Benzenoacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-methyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 819810-96-3 CAPLUS
 CN Piperazine, 1-(2-cyanophenyl)-4-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 819810-97-4 CAPLUS
 CN Benzenoacetic acid, 3-hydroxy-2-(4-methoxybenzoyl)-5-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 819811-15-9 CAPLUS
CN Piperazine, 1-acetyl-4-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 819811-16-0 CAPLUS
CN Piperazine, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 819811-17-1 CAPLUS
CN Isoquinoline, 2-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 819811-18-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-N-(2-furanylmethyl)-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 819811-19-3 CAPLUS
CN 1-Piperazineethanol, 4-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-20-6 CAPLUS
CN Piperazine, 1-[(2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxyphenyl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 819811-21-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 819811-22-8 CAPLUS


CN Piperazine, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 819811-23-9 CAPLUS
CN Morpholine, 4-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 819811-24-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 819811-26-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxy-1-(hydroxymethyl)ethyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 819811-27-3 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 819811-28-4 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-29-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-33-1 CAPLUS
CN Isoquinoline, 2-[(2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxyphenyl]acetyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 819811-34-2 CAPLUS
CN Piperazine, 1-[(2-ethyl-3,5-dihydroxy-6-(4-hydroxybenzoyl)phenyl)acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 819811-35-3 CAPLUS
CN Benzenesacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-40-0 CAPLUS
CN 4-Piperidinemethanol, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 819811-43-3 CAPLUS
CN Piperazinone, 1-(3-chlorophenyl)-4-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 819811-45-5 CAPLUS
CN Benzenesacetamide, 2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-46-6 CAPLUS
CN Piperazine, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 819811-47-7 CAPLUS
CN Piperazinone, 4-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 819811-48-8 CAPLUS
CN Benzenesacetamide, 2-ethyl-N-(2-furylmethyl)-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 819811-54-6 CAPLUS
CN Piperazinone, 4-[(2-benzoyl-6-ethyl-3,5-dihydroxyphenyl)acetyl]-1-(2-cyanophenyl)- (9CI) (CA INDEX NAME)




RN 819811-55-7 CAPLUS
CN Benzenesacetamide, 2-benzoyl-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-56-8 CAPLUS
CN Benzenesacetamide, 2-benzoyl-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-57-9 CAPLUS
CN 4-Piperidinemethanol, 1-[(2-benzoyl-6-ethyl-3,5-dihydroxyphenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 819811-58-0 CAPLUS
CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-6-(3-hydroxybenzoyl)-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-59-1 CAPLUS
CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-6-(4-hydroxybenzoyl)-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-60-4 CAPLUS
CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-6-(4-hydroxybenzoyl)-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-61-5 CAPLUS
CN Piperazinone, 4-[(2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxyphenyl)acetyl]-1-phenyl- (9CI) (CA INDEX NAME)







RN 819811-62-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(3-hydroxy-4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 819811-63-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(3-hydroxy-4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-64-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(3-fluoro-4-methoxybenzoyl)-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-65-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(3-fluoro-4-methoxybenzoyl)-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-66-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(4-(trifluoromethoxy)benzoyl)- (9CI) (CA INDEX NAME)




RN 819811-67-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)




RN 819811-68-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(3-hydroxy-4-methoxybenzoyl)-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-69-3 CAPLUS
CN Benzeneacetamide, 2-[4-(difluoromethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-70-6 CAPLUS
CN Benzeneacetamide, 2-[4-(difluoromethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-71-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(3-hydroxy-4-methylbenzoyl)- (9CI) (CA INDEX NAME)




RN 819811-72-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(3-hydroxy-4-methylbenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-73-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-hydroxypropyl)-6-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)




RN 819811-74-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(methylthio)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-75-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-[4-(methylsulfonyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 819811-76-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(methylsulfonyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 819811-77-3 CAPLUS
 CN 2-Pyrrolidinemethanol, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 819811-78-4 CAPLUS
 CN Benzenacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 819811-79-5 CAPLUS
 CN Benzenacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3-(furanylmethyl)-3,5-dihydroxy-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-80-8 CAPLUS
 CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-hydroxypropyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 819811-81-9 CAPLUS
 CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-6-(3-(2-hydroxyethyl)-4-methoxybenzoyl)-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-82-0 CAPLUS
 CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-methoxy-3-(2-methoxyethoxy)benzoyl]- (9CI) (CA INDEX NAME)




RN 819811-83-1 CAPLUS
 CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-methoxy-3-[2-(4-morpholinyl)ethoxy]benzoyl)- (9CI) (CA INDEX NAME)




RN 819811-84-2 CAPLUS
 CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-hydroxy-3-


methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-85-3 CAPLUS
 CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-6-(4-hydroxy-3-methoxybenzoyl)-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-86-4 CAPLUS
 CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-(4-methylsulfonyl)benzoyl)- (9CI) (CA INDEX NAME)




RN 819811-87-5 CAPLUS
 CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-6-(4-(2-hydroxyethoxy)-3-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-88-6 CAPLUS


CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxy-4-(2-methoxyethoxy)benzoyl)- (9CI) (CA INDEX NAME)




RN 819811-89-7 CAPLUS
 CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxy-4-[2-(4-morpholinyl)ethoxy]benzoyl)- (9CI) (CA INDEX NAME)




RN 819811-90-0 CAPLUS
 CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-(4-morpholinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 819811-91-1 CAPLUS
 CN Benzenacetamide, 2-(3,4-dimethoxybenzoyl)-N-[2-(dimethylamino)ethyl]-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-92-2 CAPLUS
CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)





RN 819811-93-3 CAPLUS
CN Benzeneacetamide, N-[2-(diethylamino)ethyl]-2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-94-4 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819811-95-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819811-96-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(3-hydroxypropyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-97-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 819811-98-8 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(3-hydroxypropyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-99-9 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 819812-00-5 CAPLUS
CN Benzeneacetamide, 2-(4-ethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)





RN 819812-01-6 CAPLUS
CN Benzeneacetamide, 2-(4-ethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-02-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-[4-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)




RN 819812-03-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-[4-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)




RN 819812-04-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl]- (9CI) (CA INDEX NAME)




RN 819812-05-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-[4-(2-hydroxyethoxy)-3-methoxybenzoyl]-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-06-1 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-N-[3-(dimethylamino)propyl]-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-07-2 CAPLUS
CN Benzeneacetamide, N-[3-(dimethylamino)propyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-08-3 CAPLUS
CN Benzenacetamide, N-[2-(diethylamino)ethyl]-2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-09-4 CAPLUS
CN Benzenacetamide, N-[2-(diethylamino)ethyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-10-7 CAPLUS
CN Piperidine, 1-[(2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxyphenyl)acetyl]-4-(morpholinyl)- (9CI) (CA INDEX NAME)




RN 819812-11-8 CAPLUS
CN Piperidine, 1-[(2-(3,4-bis(2-methoxyethoxy)benzoyl)-6-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-4-(morpholinyl)- (9CI) (CA INDEX NAME)




RN 819812-12-9 CAPLUS
CN Benzenacetamide, 2-(4-ethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819812-13-0 CAPLUS
CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-6-(2-methoxyethyl)-6-(4-(1-methylethoxy)benzoyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819812-14-1 CAPLUS
CN Benzenacetamide, 2-bromo-3,5-dihydroxy-6-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-15-2 CAPLUS
CN Benzenacetamide, 2-acetyl-3,5-dihydroxy-6-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-16-3 CAPLUS
CN Benzenacetamide, 2-[3,4-bis(2-methoxyethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-17-4 CAPLUS
CN Benzenacetamide, 2-[3,4-bis(2-methoxyethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-18-5 CAPLUS
CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-(3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 819812-19-6 CAPLUS
CN Benzenacetamide, N-(2-(dimethylamino)ethyl)-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 819812-20-9 CAPLUS
CN Benzenacetamide, 2-(3,4-dimethoxybenzoyl)-N-[2-(dimethylamino)ethyl]-6-ethyl-3,5-dihydroxy-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 819812-21-0 CAPLUS
CN Benzenacetamide, N-[2-(dimethylamino)ethyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(3-methoxypropyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 819812-22-1 CAPLUS
CN Benzenacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(trifluoromethyl)benzoyl- (9CI) (CA INDEX NAME)




RN 819812-23-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 819812-24-3 CAPLUS
CN Benzeneacetamide, 2-(3,4-difluorobenzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-25-4 CAPLUS
CN Benzeneacetamide, 2-(3,4-difluorobenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-26-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-(2-(1-piperidinyl)ethoxy]benzoyl]- (9CI) (CA INDEX NAME)




RN 819812-27-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[3-(4-morpholinyl)-1-piperidinyl]ethoxy]benzoyl]- (9CI) (CA INDEX NAME)




RN 819812-28-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[3-(4-morpholinyl)propoxy]benzoyl]- (9CI) (CA INDEX NAME)




RN 819812-29-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-(2-(4-methyl-1-piperazinyl)-2-oxoethoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-36-7 CAPLUS
CN Benzeneacetamide, 2-(1,3-benzodioxol-5-ylcarbonyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-37-0 CAPLUS
CN Benzeneacetamide, 2-(1,3-benzodioxol-5-ylcarbonyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:451630 CAPLUS Full-text
DOCUMENT NUMBER: 141:23557
TITLE: Preparation of (R)-2,3-benzodiazepines for the treatment of neutropenia.
INVENTOR(S): Harris, Herbert W.; Kucharik, Robert F.
PATENT ASSIGNEE(S): Vela Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004106601	A1	20040603	US 2002-309527	20021203
US 7022700	B2	20060404		
US 2004138210	A1	20040715	US 2003-728266	20031202
WO 2004050615	A2	20040617	WO 2003-US38634	20031203
WO 2004050615	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MO, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW RM: BM, GH, GM, KS, LS, MM, MZ, SD, SL, SZ, TZ, UO, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO				
AU 2003302682	A1	20040623	AU 2003-302682	20031203
PRIORITY APPLN. INFO.:			US 2002-309527	20021203

NO 2003-US38634 * 20031203

OTHER SOURCE(S): MARPAT 141:23557
ED Entered STN: 04 Jun 2004
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = alkylhydrocarbyl, heteroalkyl; R2 = H, hydrocarbyl, wherein R1 and R2 may combine to form a carbocyclic or heterocyclic 5- or 6-membered ring; X = (R3); R3 = O-alkyl, OH, O-acyl, etc.; n = 1-3; R4, R5 = O-alkyl, OH, O-acyl, etc., wherein R4 and R5 may combine to form a 5-, 6-, 7-membered heterocyclic ring] and their pharmaceutically acceptable salts were prepared. For example, condensation-cyclization of diketone II, e.g., prepared from 3-methoxy-4-hydroxybenzoic acid in 7-steps, and hydrazine hydrate afforded racemic benzodiazepine III. In a 16-day study of neutrophil production in rats, one example of compound I, e.g., R-tol isopam, significantly increased neutrophil levels in a dose-dependent manner. Compds. I are claimed for increasing the production of neutrophils.


IT 618056-34-1P, 3-[4-(5-Dimethoxy-2-[(4-methoxy-3-(phenylmethoxy)phenyl]phenyl]pentan-2-one 618056-36-3P, 3-(4-Benzoyloxy-4-methoxyphenyl)carbonyl]phenyl]pentan-2-one 618056-39-6P, 3-[4-Benzoyloxy-5-methoxy-2-[(3,4-dimethoxyphenyl)carbonyl]phenyl]pentan-2-one 697754-57-7P, 3-[2-(3,4-Dimethoxyphenyl)carbonyl]-4-hydroxy-5-methoxyphenyl]pentan-2-one.

RL: RCT (Reactant); SPN (Synthetic preparation); PRP (Preparation); RACT (Reactant or reagent)
(preparation of benzodiazepines for the treatment of neutropenia.)


RN 618056-34-1 CAPLUS
CN 2-Pentanone, 3-[4,5-dimethoxy-2-(4-methoxy-3-(phenylmethoxy)benzoyl)phenyl]- (CA INDEX NAME)




RN 618056-36-3 CAPLUS
CN 2-Pentanone, 3-[2-(3-hydroxy-4-methoxybenzoyl)-4,5-dimethoxyphenyl]- (CA INDEX NAME)




RN 618056-39-6 CAPLUS
CN 2-Pentanone, 3-[2-(3,4-dimethoxybenzoyl)-5-methoxy-4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 697754-57-7 CAPLUS
CN 2-Pentanone, 3-[2-(3,4-dimethoxybenzoyl)-4-hydroxy-5-methoxyphenyl]- (CA INDEX NAME)




LS2 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:326400 CAPLUS Full-text
DOCUMENT NUMBER: 139:374215
TITLE: Synthesis and cytotoxic activity of 1,3-benzodioxole derivatives. Note II
AUTHOR(S): Micali, Nicola; Zappala, Maria; Grasso, Silvana
CORPORATE SOURCE: Dipartimento Farmaco-Chimico, Universita di Messina, Messina, 98168, Italy
SOURCE: Farmaco (2003), 58(5), 351-355
CODEN: FRMCB8; ISSN: 0014-827X
PUBLISHER: Editiones Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:374215
ED Entered STN: 29 Apr 2003
AB A series of 1,3-benzodioxoles (2-12) were synthesized and evaluated for their in vitro ability to inhibit the growth of three human tumor cell lines. No cytotoxic effects were noticed with any of the test compds. at a concentration of 10-4 M.
IT 132813-95-7P 197369-12-3P 501328-34-3P
623944-58-1P 623944-59-2P 623944-65-0P
623944-66-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and cytotoxic activity of 1,3-benzodioxole derive.)
RN 132813-95-7 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-benzoyl-, methyl ester (CA INDEX NAME)




RN 197369-12-3 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-fluorobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 501328-34-3 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-aminobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 623944-58-1 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-chlorobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 623944-59-2 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-aminobenzoyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 623944-65-0 CAPLUS
CN 1,3-Benzodioxole-5-acetamide, N-methyl-6-(4-nitrobenzoyl)- (9CI) (CA INDEX NAME)




RN 623944-66-1 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-nitrobenzoyl)-, hydrazide (9CI) (CA INDEX NAME)




IT 197369-14-5P 209851-94-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and cytotoxic activity of 1,3-benzodioxole derive.)

RN 197369-14-5 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-nitrobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 209851-94-5 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-nitrobenzoyl)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS2 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:907951 CAPLUS Full-text
DOCUMENT NUMBER: 138:237975
TITLE: Synthesis and antitumor activity of 1,3-benzodioxole derivatives
AUTHOR(S): Micali, Nicola; Zappala, Maria; Grasso, Silvana
CORPORATE SOURCE: Dipartimento Farmaco-Chimico, Universita di Messina, Messina, 98168, Italy
SOURCE: Farmaco (2002), 57(10), 853-859
CODEN: FRMCB8; ISSN: 0014-827X
PUBLISHER: Editiones Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:237975
ED Entered STN: 01 Dec 2002
GI




AB A series of 1,3-benzodioxoles was synthesized and evaluated for their in vitro antitumor activity against human tumor cell lines. Some derivs. exhibited tumor growth inhibition activity. In particular, 6-(4-aminobenzoyl)-1,3-benzodioxole-5-acetic acid Me ester (I), the most active compound of the series, possesses a significant growth inhibitory activity on 52 cell lines at concns. ranging from 10-7 to 10-5 M.

IT 197369-14-5P 433716-67-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of a series of 1,3-benzodioxoles from 1,3-benzodioxole-5-acetonitrile and evaluation of their antitumor activity)

RN 197369-14-5 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-nitrobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)

RN 77605-57-3 CAPLUS
 CN Benzeneacetic acid, 2-benzoyl-4-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996-417842 CAPLUS Full-text
 DOCUMENT NUMBER: 125-76353
 TITLE: Inhibitors of farnesyl-protein transferase
 INVENTOR(S): Stokker, Gerald B.; Graham, Samuel L.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA; Stokker, Gerald, B.; Graham, Samuel, L.
 SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9610011	A1	19960404	WO 1995-US12321	19950925
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ				
RM: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5523456	A	19960604	US 1994-315046	19940929
CA 2201351	A1	19960404	CA 1995-2201351	19950925
AU 9536426	A	19960419	AU 1995-36426	19950925
AU 689651	B2	19980402		
EP 787123	A1	19970806	EP 1995-933957	19950925
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 10506898	T	19980707	JP 1996-511981	19950925
PRIORITY APPLN. INFO.:			US 1994-315046	A2 19940929
			NO 1995-US12321	W 19950925

ED Entered STN: 17 Jul 1996
 AB The present invention comprises analogs of the CAAX motif of the protein Ras that is modified by farnesylation in vivo. These CAAX analogs inhibit the farnesylation of Ras. Furthermore, these CAAX analogs differ from those previously described as inhibitors of Ras farnesyl transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid auto-oxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compns. containing these farnesyl transferase inhibitors and methods for their production

NARROWER STRUCTURE SEARCH

```
>> fil reg; d stat que 142; fil capl
FILE 'REGISTRY' ENTERED AT 15:09:42 ON 15 JUN 2007
USER IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZINC/VINICI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3
 DICTIONARY FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.acs.org/support/stn/reg/stndoc/properties.html>

L8 STR




NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
 L11 625 SEA FILE=REGISTRY SSS FUL L8
 L35 STR



IT 178449-02-0P 178449-18-EP
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRP (Preparation); USES (Uses)
 (preparation of analogs of CAAX motif of protein Ras for inhibiting Ras farnesyl-transferase and for treating cancer)
 RN 178449-02-0 CAPLUS
 CN L-Methionine, N-[N-[2-[(2-benzoylphenyl)acetyl]amino]-4-methylpentyl]-N-(1-naphthalenylmethyl)glycyl-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178449-18-8 CAPLUS
 CN L-Methionine, N-[N-[2-[(2-benzoylphenyl)acetyl]amino]-4-methylpentyl]-N-(1-naphthalenylmethyl)glycyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



0.019 0.020

VPA 19-9/10/11/12 U

VPA 20-1/2/4/5/6 U

NODE ATTRIBUTES:

NSPEC 18 RC AT 16

DEFAULT MLEVEL IS ATOM

DEFAULT ELEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

L19 STR



0.018 0.019

VPA 18-9/10/11/12 U

VPA 19-9/10/11/12 U

NODE ATTRIBUTES:

NSPEC 18 RC AT 16

DEFAULT MLEVEL IS ATOM

DEFAULT ELEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

L19 STR



0.020 0.021

VPA 20-1/2/4/5/6 U
 VPA 21-1/2/4/5/6 U
 NODE ATTRIBUTES:
 NSPEC IS RC AT 16
 DEFAULT LEVEL IS ATOM
 DEFAULT SCLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 20

Stereo ATTRIBUTES: NONE
 L42 151 SEA FILE=REGISTRY SUB=L11 SSS FUL (L35 OR L38 OR L39)

100.0% PROCESSED 193 ITERATIONS 151 ANSWERS
 SEARCH TIME: 00:00.01

FILE 'CAPLUS' ENTERED AT 15:09:42 ON 15 JUN 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The Ca Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of ACS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2007 VOL 146 ISS 26
 FILE LAST UPDATED: 14 Jun 2007 (20070614/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
 They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE


```
>> d que nos 143; s 143 not 144,152
L6      STR
L11     625 SEA FILE=REGISTRY SSS FUL L6
L35     STR
L38     STR
L39     STR
L42     151 SEA FILE=REGISTRY SUB=L11 SSS FUL (L35 OR L38 OR L39)
L43     5 SEA FILE=CAPLUS ABB=ON L42
```

L53 3 L43 NOT (L44 OR L52)


>> d ibib ed abs hitstr 1-3; fil hom

L53 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:406217 CAPLUS Full-text
 Correction of: 2005:155220
 DOCUMENT NUMBER: 143:266757
 Correction of: 142:197771
 TITLE: Product class 5: isoquinolines
 AUTHOR(S): Alvarez, M.; Joule, J. A.
 CORPORATE SOURCE: Germany
 SOURCE: Science of Synthesis (2005), 15, 661-838
 CODEN: SSCOYJ9
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 ED Entered STN: 13 May 2005
 AB A review primarily covering methods of preparation of isoquinolines via cyclization, ring transformations or substituent modification. Isoquinoline 2-oxides and isoquinolinium salts are also included.
 IT 180072-41-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of isoquinolines and analogs via cyclization, ring transformations or substituent modifications)
 RN 180072-41-7 CAPLUS
 CN Benzeneacetamide, N-[{(1R)-2-hydroxy-1-phenylethyl}-4,5-dimethoxy-2-(3,4,5-trimethoxybenzoyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L53 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:376527 CAPLUS Full-text
 DOCUMENT NUMBER: 125:167761
 TITLE: Asymmetric synthesis. XLII. Totally stereoselective synthesis of 1,3-disubstituted tetrahydroisoquinolines via the CH(R,S) method
 AUTHOR(S): Goemann, Grace; Guillaume, Dominique; Husson, Henri-Philippe
 CORPORATE SOURCE: Lab. Chimie Therapeutique associe CNRS, Univ. R. Descartes, Paris, 75270, Fr.
 SOURCE: Tetrahedron Letters (1996), 37(25), 4369-4372
 CODEN: TLEBLA; ISSN: 0040-4039
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 125:167761
 ED Entered STN: 28 Jun 1996
 GI




AB Optically active cis- or trans- 1,3-disubstituted tetrahydroisoquinolines 3-R or 3S-I (R = Me, CH₂Ph) can be prepared selectively from the same oxazolidine II. This latter is easily obtained from keto-acid III and (R)-(-)-phenylglycinol.
 IT 180072-41-7P
 RL: RCT (Reactant); BPN (Synthetic preparation); PRSP (Preparation); RACT (Reactant or reagent)
 (stereoselective preparation of isoquinolines)
 RN 180072-41-7 CAPLUS
 CN Benzeneacetamide, N-[(1R)-2-hydroxy-1-phenylethyl]-4,5-dimethoxy-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L53 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1974:108242 CAPLUS Full-text
 DOCUMENT NUMBER: 80:108242
 TITLE: Tetracycline studies. IV. Novel cyclizations through benzophenone carbanions, including a new synthesis of anthraquinones
 AUTHOR(S): Hassall, Cedric H.; Morgan, Barry A.
 CORPORATE SOURCE: Dep. Chem., Univ. Coll. Swansea, Swansea, UK
 SOURCE: Journal of the Chemical Society, Perkin Transactions

1: Organic and Bio-Organic Chemistry (1972-1999)
 1 (1973), (23), 2053-61
 CODEN: JCPRB4; ISSN: 0300-922X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 12 May 1984
 GI For diagram(s), see printed CA Issue.
 AB 2,3,5-Me₃O-C₆H₂CH₂CN with 2,4,6,3-(MeO)₃C₆HCO₂H in (P₃CCO)₂₀ gave 71% benzophenone (I) which with NaOMe in DMP gave 95% anthrol (II). II with H₂O₂ and NaOH gave 96% 1,3,6,8-tetramethoxy-2-(methoxycarbonyl)-5-methylenanthraquinone which gave the 6-methylpretetrasid analog (III) in 3 steps. Other anthraquinones including emodin and physcion were prepared similarly.
 IT 52344-90-8P
 RL: BPN (Synthetic preparation); PRSP (Preparation)
 (preparation of)
 RN 52344-90-8 CAPLUS
 CN Benzeneacetamide, N-2-bis(2,6-dimethoxybenzoyl)-3,5-dimethoxy- (9CI) (CA INDEX NAME)



FILE 'HOME' ENTERED AT 15:10:23 ON 15 JUN 2007


10/561415

STIC

SEARCH HISTORY

> d stat que 142; d his nofile


L6 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L11 625 SEA FILE-REGISTRY SSS FUL L6
L35 STR



VPA 19-9/10/11/12 U

VPA 20-1/2/4/5/6 U

NODE ATTRIBUTES:
NSPEC IS RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT ELEVEL IS LIMITED


GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L38 STR

0.819 0.820

10/561415

STIC




VPA 18-9/10/11/12 U

VPA 19-9/10/11/12 U

NODE ATTRIBUTES:
NSPEC IS RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L39 STR



0.820 0.821

VPA 20-1/2/4/5/6 U

VPA 21-1/2/4/5/6 U

NODE ATTRIBUTES:
NSPEC IS RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L42 151 SEA FILE-REGISTRY SUB-L11 SSS FUL (L35 OR L38 OR L39)

100.0% PROCESSED 193 ITERATIONS 151 ANSWERS
SEARCH TIME: 00.00.01

(FILE 'HOME' ENTERED AT 14:40:53 ON 15 JUN 2007)

FILE 'REGISTRY' ENTERED AT 14:41:33 ON 15 JUN 2007

98

97

10/561415

STIC

L1 STR
L2 5 SEA SSS SAM L1

FILE 'ZCAPLUS' ENTERED AT 14:44:51 ON 15 JUN 2007
L3 2 SEA ABB-ON L2
D SCAN TI

FILE 'REGISTRY' ENTERED AT 14:45:22 ON 15 JUN 2007

L4 STR L1
L5 5 SEA SSS SAM L4L6 STR L4
L7 11 SEA SSS SAM L6L8 STR L6
L9 33 SEA SSS SAM L8

L10 5028 SEA SSS FUL L8 EXTEND

L11 625 SEA SSS FUL L8
SAVE TEMP L11 HAV415FULL/A

FILE 'ZCAPLUS' ENTERED AT 14:47:02 ON 15 JUN 2007
L12 283 SEA ABB-ON L11

FILE 'REGISTRY' ENTERED AT 14:48:19 ON 15 JUN 2007

L13 STR L8
L14 STR L4L15 STR L4
L16 22 SEA SUB-L11 SSS SAM (L13 OR L14 OR L15)

FILE 'STNGUIDE' ENTERED AT 14:52:39 ON 15 JUN 2007

FILE 'ZCAPLUS' ENTERED AT 14:52:47 ON 15 JUN 2007
L17 23 SEA ABB-ON L16

FILE 'REGISTRY' ENTERED AT 14:53:43 ON 15 JUN 2007

L18 STR L4
L19 5 SEA SUB-L11 SSS SAM L18

L20 5 SEA ABB-ON L5 AND L19

FILE 'CAPLUS' ENTERED AT 14:54:46 ON 15 JUN 2007

E US2005-561415/APPS
L21 1 SEA ABB-ON US2005-561415/APD SCAN
SER RN

FILE 'REGISTRY' ENTERED AT 14:55:14 ON 15 JUN 2007

L22 412 SEA ABB-ON (100-09-4/B1 OR 100-52-7/B1 OR 103-76-4/B1 OR
10365-98-7/B1 OR 106-95-6/B1 OR 109-01-3/B1 OR 109-70-6/B1 OR
109-83-1/B1 OR 109-85-3/B1 OR 109284-19-2/B1 OR 110-87-2/B1 OR
110-91-8/B1 OR 111-42-2/B1 OR 111-95-5/B1 OR 111373-03-6/B1 OR
123-11-5/B1 OR 126495-72-5/B1 OR 13205-46-4/B1 OR 13205-48-6/B1
OR 13889-98-0/B1 OR 141699-59-4/B1 OR 16015-71-7/B1 OR
1694-92-4/B1 OR 17739-45-6/B1 OR 18226-11-4/B1 OR 183322-16-9/B
I OR 183500-94-9/B1 OR 189205-49-0/B1 OR 19344-29-7/B1 OR
20173-04-0/B1 OR 208245-69-6/B1 OR 214360-76-6/B1 OR 2328-12-3/
BI OR 290328-55-1/B1 OR 3240-94-6/B1 OR 329-15-7/B1 OR
330-12-1/B1 OR 331-64-6/B1 OR 34328-61-5/B1 OR 34750-64-6/B1
OR 34841-06-0/B1 OR 3485-05-0/B1 OR 351-54-2/B1 OR 3647-69-6/B1
OR 3731-52-0/B1 OR 38256-93-8/B1 OR 39216-84-7/B1 OR 3943-89-3
/B1 OR 39546-32-2/B1 OR 40137-22-2/B1 OR 40499-03-0/B1 OR
40807-61-2/B1 OR 4138-26-5/B1 OR 4439-22-9/B1 OR 456-22-4/B1
OR 4606-65-9/B1 OR 4724-10-1/B1 OR 4753-75-7/B1 OR 4837-20-1/B1

10/561415

STIC

OR 488-93-7/B1 OR 51254-17-2/B1 OR 527-72-0/B1 OR 5332-73-0/B1
OR 53617-35-9/B1 OR 5407-04-5/B1 OR 54093-33-3/B1 OR 555-16-5/
B1 OR 586-38-9/B1 OR 59817-32-2/B1 OR 621-51-2/B1 OR 722-26-4/B
I OR 627-30-5/B1 OR 645-08-9/B1 OR 6457-49-4/B1 OR 6482-24-2/B1
OR 65-85-0/B1 OR 6859-99-0/B1 OR 68832-13-3/B1 OR 6663-77-6/B1
OR 76903-88-3/B1 OR 819810-73-6/B1 OR 819810-75-0/B1 OR
819810-77-0/B1 OR 819810-79-2/B1 OR 819810-81-6/B1 OR 819810-82-
7/B1 OR 819810-83-8/B1 OR 819810-85-0/B1 OR 819810-87-2/B1 OR
819810-89-4/B1 OR 819810-90-7/B1 OR 819810-91-8/B1 OR 819810-92-
9/B1 OR 819810-93-0/B1 OR 819810-94-1/B1 OR 819810-95-2/B1 OR
819810-96-3/B1 OR 819810-97-4/B1 OR 819810-98-5/B1 OR 819810-99-
6/B1 OR 819811-00-2/B1 OR 819811-01-3/B1 OR 819811-02-4/B1 OR
819811-03-5/B1 OR 819811-04-6/B1 OR 819811-05-7/B1 OR 819811-06-
8/B1 OR 819811-07-9/B1 OR 819811-08-0/B1 OR 819811-09-1/B1 OR
819811-10-4/B1 OR 819811-11-5/B1 OR 819811-12-6/B1 OR 819811-13-
7/B1 OR 819811-14-8/B1 OR 819811-15-9/B1 OR 819811-16-0/D1 OR
819811-17-1/B1 OR 819811-18-2/B1 OR 819811-19-3/B1 OR 819811-
220 SEA ABB-ON L22 AND L11
L24 254 SEA ABB-ON L11 AND H/L5

FILE 'ZCAPLUS' ENTERED AT 14:57:24 ON 15 JUN 2007

L25 74 SEA ABB-ON L24

FILE 'REGISTRY' ENTERED AT 14:57:42 ON 15 JUN 2007

L26 191 SEA ABB-ON L24 AND 5<0

FILE 'ZCAPLUS' ENTERED AT 14:57:48 ON 15 JUN 2007

L27 39 SEA ABB-ON L26

FILE 'REGISTRY' ENTERED AT 14:58:02 ON 15 JUN 2007

L28 52 SEA ABB-ON L26 NOT L22

L29 15175 SEA ABB-ON NITROBRNZ

L30 52 SEA ABB-ON L28 NOT L29

L31 0 SEA ABB-ON L28 AND L29

L32 118258 SEA ABB-ON NITROBRNZ?

L33 11 SEA ABB-ON L28 NOT L32
D SCAN

FILE 'ZCAPLUS' ENTERED AT 15:01:47 ON 15 JUN 2007

L34 12 SEA ABB-ON L33

FILE 'REGISTRY' ENTERED AT 15:02:33 ON 15 JUN 2007

L35 STR L4

L36 9 SEA SUB-L11 SSS SAM L35

L37 0 SEA ABB-ON L36 NOT L22

L38 STR L4

L39 STR L4

L40 9 SEA SUB-L11 SSS SAM (L35 OR L38 OR L39)

L41 193 SEA SUB-L11 SSS FUL (L35 OR L38 OR L39) EXTEND

L42 151 SEA SUB-L11 SSS FUL (L35 OR L38 OR L39)

SAVE TEMP L42 HAV415SUB9/A

FILE 'CAPLUS' ENTERED AT 15:05:36 ON 15 JUN 2007

L43 . 5 SEA ABB-ON L42

L44 1 SEA ABB-ON L21 OR (L21 AND L43)

D SCAN

L45 29025 SEA ABB-ON HEAT SHOCK/OBI OR HSP90/OBI OR HSP/OBI

L46 283 SEA ABB-ON L11

L47 283 SEA ABB-ON L11

99

100

10/561415

STIC

L46 1 SEA ABB-ON L47 AND L45
L49 166137 SEA ABB-ON ANTITUMOR AGENTS/CT
L50 484200 SEA ABB-ON NEOPLAS?/OBI
L51 8 SEA ABB-ON L47 AND (L49 OR L50)

FILE 'CAPLUS' ENTERED AT 15:08:14 ON 15 JUN 2007
D QUB NOS L44
D IBIS ED ABS HITSTR L44

FILE 'REGISTRY' ENTERED AT 15:08:48 ON 15 JUN 2007
D STAT QUB L11

FILE 'CAPLUS' ENTERED AT 15:08:48 ON 15 JUN 2007
D QUB NOS L46
D QUR NOS L51

L52 7 SEA ABB-ON (L48 OR L51) NOT L44
D IBIS ED ABS HITSTR 1-7

FILE 'REGISTRY' ENTERED AT 15:09:42 ON 15 JUN 2007
D STAT QUB L42

FILE 'CAPLUS' ENTERED AT 15:09:42 ON 15 JUN 2007
D QUB NOS L43
L53 3 SEA ABB-ON L43 NOT (L44 OR L52)
D IBIS ED ABS HITSTR 1-3

FILE 'HOME' ENTERED AT 15:10:23 ON 15 JUN 2007
D STAT QUB L42

-->

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	5	("7115651" "7074770").pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 13:36
S2	6	"561415".ap.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/13 08:55
S3	2	"7022700".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/20 17:27
S4	7	"309527".ap.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/20 17:32
S5	2	"6495560".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/20 17:33
S6	2	"5523456".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/20 17:33